RxDoctor Payments Data

Cory Waldman, MD

Cardiovascular Disease · Beverly Hills, CANPI 1740445774

Payments from drug & device makers

$5,218in general payments, 2019–2025

Across 270 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$981
  • AbbVie$865
  • Novartis$481
  • Pfizer$412
  • Lilly USA, LLC$361
  • Novo Nordisk$222
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$5,218100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,218 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$656,302
Medicare patients
641
Services billed
14,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$205,724
Humira(Cf) PenAdalimumab12$96,389
Repatha SureclickEvolocumab106$70,381
MounjaroTirzepatide53$57,376
OzempicSemaglutide51$47,954
JardianceEmpagliflozin41$37,526
DescovyEmtricitabine/Tenofov Alafenam11$24,298
XareltoRivaroxaban25$20,866
Repatha SyringeEvolocumab26$20,622
EntrestoSacubitril/Valsartan23$19,566
LivaloPitavastatin Calcium39$18,896
SynthroidLevothyroxine Sodium260$17,726
RestasisCyclosporine21$12,793
NamzaricMemantine Hcl/Donepezil Hcl20$11,699
Praluent PenAlirocumab21$10,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$412$211,642333 claims
Lilly USA, LLCMounjaro$361$57,37653 claims
Novo NordiskOzempic$222$47,95451 claims
AbbVieSynthroid, Restasis, Namzaric$865$42,217301 claims
Boehringer IngelheimJardiance$25$37,52641 claims
Johnson & JohnsonXarelto$25$20,86625 claims
NovartisEntresto$481$19,56623 claims
Kowa Pharmaceuticals America, Inc.Livalo$97$18,89639 claims
MerckBelsomra$43$4,92011 claims
Arbor Pharmaceuticals, Inc.Edarbi$57$4,20413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →